{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:16:08Z","timestamp":1747152968540,"version":"3.40.5"},"publisher-location":"Cham","reference-count":48,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030502478"},{"type":"electronic","value":"9783030502478"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-030-50247-8_130-1","type":"book-chapter","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T15:04:37Z","timestamp":1660835077000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacoeconomic Analysis Methods"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S.","family":"Tonin","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-3120","authenticated-orcid":false,"given":"Leticia P.","family":"Leonart","sequence":"additional","affiliation":[]},{"given":"Cesar","family":"Casas","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"issue":"4","key":"130-1_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1365-2125.2012.04421.x","volume":"75","author":"Z Ademi","year":"2013","unstructured":"Ademi Z, Kim H, Zomer E, Reid CM, Hollingsworth B, Liew D. Overview of pharmacoeconomic modelling methods. Br J Clin Pharmacol. 2013;75(4):944\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"130-1_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fphar.2017.00384","volume":"8","author":"N Allen","year":"2017","unstructured":"Allen N, Liberti L, Walker SR, Salek S. A comparison of reimbursement recommendations by European HTA agencies: is there opportunity for further alignment? Front Pharmacol. 2017;8:384.","journal-title":"Front Pharmacol"},{"issue":"6","key":"130-1_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1524-4733.2000.36007.x","volume":"3","author":"L Annemans","year":"2000","unstructured":"Annemans L, Geneste B, Jolain B. Early modelling for assessing health and economic outcomes of drug therapy. Value Health. 2000;3(6):427\u201334.","journal-title":"Value Health"},{"issue":"11","key":"130-1_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jama.2019.1153","volume":"321","author":"A Basu","year":"2019","unstructured":"Basu A, Maciejewski ML. Choosing a time horizon in cost and cost-effectiveness analyses. JAMA. 2019;321(11):1096\u20137.","journal-title":"JAMA"},{"issue":"4","key":"130-1_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1046\/j.1524-4733.1998.140201.x","volume":"1","author":"M Berger","year":"1998","unstructured":"Berger M. Willingness to pay versus willingness to buy: what defines value in healthcare? Value Health. 1998;1(4):201\u20133.","journal-title":"Value Health"},{"issue":"12","key":"130-1_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925\u201330.","journal-title":"Bull World Health Organ"},{"issue":"8","key":"130-1_CR7","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/j.1524-4733.2009.00590.x","volume":"12","author":"HC Boshuizen","year":"2009","unstructured":"Boshuizen HC, van Baal PH. Probabilistic sensitivity analysis: be a Bayesian. Value Health. 2009;12(8):1210\u20134.","journal-title":"Value Health"},{"issue":"3","key":"130-1_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","volume":"22","author":"J Brazier","year":"2019","unstructured":"Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Severac H, Crawford B, et al. Identification, review, and use of health state Utilities in Cost-Effectiveness Models: an ISPOR good practices for outcomes research task force report. Value Health. 2019;22(3):267\u201375.","journal-title":"Value Health"},{"issue":"4","key":"130-1_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00019053-200523040-00002","volume":"23","author":"JF Bridges","year":"2005","unstructured":"Bridges JF. Future challenges for the economic evaluation of healthcare: patient preferences, risk attitudes and beyond. PharmacoEconomics. 2005;23(4):317\u201321.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"130-1_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/hec.766","volume":"12","author":"A Briggs","year":"2003","unstructured":"Briggs A, Clark T, Wolstenholme J, Clarke P, Missing... Presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12(5):377\u201392.","journal-title":"Health Econ"},{"issue":"10","key":"130-1_CR11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/hec.1422","volume":"18","author":"MK Chapko","year":"2009","unstructured":"Chapko MK, Liu CF, Perkins M, Li YF, Fortney JC, Maciejewski ML. Equivalence of two healthcare costing methods: bottom-up and top-down. Health Econ. 2009;18(10):1188\u2013201.","journal-title":"Health Econ"},{"issue":"13","key":"130-1_CR12","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2009.1409","volume":"302","author":"FM Clement","year":"2009","unstructured":"Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437\u201343.","journal-title":"JAMA"},{"issue":"2","key":"130-1_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/jep.13321","volume":"26","author":"OC Damman","year":"2020","unstructured":"Damman OC, Jani A, de Jong BA, Becker A, Metz MJ, de Bruijne MC, et al. The use of PROMs and shared decision-making in medical encounters with patients: an opportunity to deliver value-based health care to patients. J Eval Clin Pract. 2020;26(2):524\u201340.","journal-title":"J Eval Clin Pract"},{"issue":"2","key":"130-1_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jval.2017.12.008","volume":"21","author":"PM Danzon","year":"2018","unstructured":"Danzon PM, Drummond MF, Towse A, Pauly MV. Objectives, budgets, thresholds, and opportunity costs-a health economics approach: an ISPOR special task force report [4]. Value Health. 2018;21(2):140\u20135.","journal-title":"Value Health"},{"key":"130-1_CR15","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2005","unstructured":"Drummond M, Sculpher M, Torrance G, O\u2019Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.","edition":"3"},{"issue":"16","key":"130-1_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5160","volume":"5","author":"M Eccles","year":"2001","unstructured":"Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess. 2001;5(16):1\u201369.","journal-title":"Health Technol Assess"},{"issue":"1","key":"130-1_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40273-015-0337-0","volume":"34","author":"EH Elbasha","year":"2016","unstructured":"Elbasha EH, Chhatwal J. Myths and misconceptions of within-cycle correction: a guide for Modelers and decision makers. PharmacoEconomics. 2016;34(1):13\u201322.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"130-1_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jval.2011.04.007","volume":"14","author":"D Epstein","year":"2011","unstructured":"Epstein D, Sutton A. Modelling correlated clinical outcomes in health technology appraisal. Value Health. 2011;14(6):793\u20139.","journal-title":"Value Health"},{"issue":"2","key":"130-1_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, et al. Value of information analysis for research decisions-an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(2):139\u201350.","journal-title":"Value Health"},{"key":"130-1_CR20","volume-title":"HTA 101: introduction to health technology assessment","author":"C Goodman","year":"2014","unstructured":"Goodman C. HTA 101: introduction to health technology assessment. Bethesda: National Library of Medicine (US); 2014."},{"issue":"8","key":"130-1_CR21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/hec.683","volume":"11","author":"N Graves","year":"2002","unstructured":"Graves N, Walker D, Raine R, Hutchings A, Roberts JA. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ. 2002;11(8):735\u20139.","journal-title":"Health Econ"},{"key":"130-1_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.vhri.2014.08.003","volume":"4","author":"D Greenberg","year":"2014","unstructured":"Greenberg D, Mohamed Ibrahim MIB, Boncz I. What are the challenges in conducting cost-of-illness studies? Value Health Reg Issues. 2014;4:115\u20136.","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"130-1_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1046\/j.1524-4733.1998.130187.x","volume":"1","author":"JW Hay","year":"1998","unstructured":"Hay JW. Economic modeling and sensitivity analysis. Value Health. 1998;1(3):187\u201393.","journal-title":"Value Health"},{"issue":"2","key":"130-1_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1\u20135.","journal-title":"Value Health"},{"issue":"7","key":"130-1_CR25","first-page":"1741","volume":"49","author":"LM Jolicoeur","year":"1992","unstructured":"Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm. 1992;49(7):1741\u20137.","journal-title":"Am J Hosp Pharm"},{"key":"130-1_CR26","volume-title":"Common problems, common data model solutions: evidence generation for health technology assessment","author":"S Kent","year":"2020","unstructured":"Kent S, Burn E, Dawoud D, Jonsson P, Ostby JT, Hughes N, et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics; 2020."},{"issue":"6","key":"130-1_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/14737167.2017.1331432","volume":"17","author":"DD Kim","year":"2017","unstructured":"Kim DD, Wilkinson CL, Pope EF, Chambers JD, Cohen JT, Neumann PJ. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):615\u201323.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"130-1_CR28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/j.1524-4733.2009.00605.x","volume":"12","author":"WF McGhan","year":"2009","unstructured":"McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. The ISPOR good practices for quality improvement of cost-effectiveness research task force report. Value Health. 2009;12(8):1086\u201399.","journal-title":"Value Health"},{"issue":"2","key":"130-1_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1783\/147118906776276549","volume":"32","author":"E McIntosh","year":"2006","unstructured":"McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: introduction to the concepts of economic evaluation in health care. J Fam Plann Reprod Health Care. 2006;32(2):107\u201312.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"6","key":"130-1_CR30","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/j.japh.2020.08.006","volume":"60","author":"EM Murphy","year":"2003","unstructured":"Murphy EM, Rodis JL, Mann HJ. Three ways to advocate for the economic value of the pharmacist in health care. J Am Pharm Assoc. 2003;60(6):e116\u2013e24.","journal-title":"J Am Pharm Assoc"},{"issue":"3","key":"130-1_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1017\/S0266462300102016","volume":"16","author":"J Nixon","year":"2000","unstructured":"Nixon J, Stoykova B, Glanville J, Christie J, Drummond M, Kleijnen J. The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology. Int J Technol Assess Health Care. 2000;16(3):731\u201342.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"130-1_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/ijic.5450","volume":"19","author":"R Nuno-Solinis","year":"2019","unstructured":"Nuno-Solinis R. Advancing towards value-based integrated Care for Individuals and Populations. Int J Integr Care. 2019;19(4):8.","journal-title":"Int J Integr Care"},{"issue":"1","key":"130-1_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-015-0325-4","volume":"34","author":"E Onukwugha","year":"2016","unstructured":"Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. PharmacoEconomics. 2016;34(1):43\u201358.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"130-1_CR34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jval.2012.06.011","volume":"15","author":"R Pitman","year":"2012","unstructured":"Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5. Value Health. 2012;15(6):828\u201334.","journal-title":"Value Health"},{"key":"130-1_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fpubh.2015.00164","volume":"3","author":"KM Rabarison","year":"2015","unstructured":"Rabarison KM, Bish CL, Massoudi MS, Giles WH. Economic evaluation enhances public health decision making. Front Public Health. 2015;3:164.","journal-title":"Front Public Health"},{"issue":"5","key":"130-1_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/cer.15.38","volume":"4","author":"R Schwarzer","year":"2015","unstructured":"Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4(5):485\u2013504.","journal-title":"J Comp Eff Res"},{"key":"130-1_CR37","volume-title":"National Healthcare Economic Evaluation Guidelines: a cross-country comparison","author":"D Sharma","year":"2021","unstructured":"Sharma D, Aggarwal AK, Downey LE, Prinja S. National Healthcare Economic Evaluation Guidelines: a cross-country comparison. Pharmacoecon Open; 2021."},{"key":"130-1_CR38","volume-title":"Building on value-based health care: towards a health system perspective","author":"PC Smith","year":"2020","unstructured":"Smith PC, Sagan A, Siciliani L, Panteli D, McKee M, Soucat A, et al. Building on value-based health care: towards a health system perspective. Copenhagen: European Observatory Policy Briefs; 2020."},{"issue":"2","key":"130-1_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/00019053-200826020-00004","volume":"26","author":"JE Stahl","year":"2008","unstructured":"Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. PharmacoEconomics. 2008;26(2):131\u201348.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"130-1_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health"},{"issue":"1","key":"130-1_CR41","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.18549\/PharmPract.2021.1.2302","volume":"19","author":"FS Tonin","year":"2021","unstructured":"Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):2302.","journal-title":"Pharm Pract (Granada)"},{"issue":"4","key":"130-1_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1017\/S0266462300008461","volume":"5","author":"GW Torrance","year":"1989","unstructured":"Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5(4):559\u201375.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"130-1_CR43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3111\/13696998.2014.907170","volume":"17","author":"HW Tuffaha","year":"2014","unstructured":"Tuffaha HW, Gordon LG, Scuffham PA. Value of information analysis in healthcare: a review of principles and applications. J Med Econ. 2014;17(6):377\u201383.","journal-title":"J Med Econ"},{"issue":"1","key":"130-1_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-020-00979-3","volume":"39","author":"RA Vreman","year":"2021","unstructured":"Vreman RA, Geenen JW, Knies S, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG. The application and implications of novel deterministic sensitivity analysis methods. PharmacoEconomics. 2021;39(1):1\u201317.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"130-1_CR45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1365-2125.1997.00574.x","volume":"43","author":"T Walley","year":"1997","unstructured":"Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol. 1997;43(4):343\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"130-1_CR46","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jval.2011.07.013","volume":"14","author":"TA Westra","year":"2011","unstructured":"Westra TA, Parouty MB, Wilschut JC, Boersma C, Postma MJ. Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis. Value Health. 2011;14(8):1173\u20134. author reply 4-5","journal-title":"Value Health"},{"key":"130-1_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5\u201321.","journal-title":"Br Med Bull"},{"issue":"1","key":"130-1_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12913-018-3456-4","volume":"18","author":"X Zhang","year":"2018","unstructured":"Zhang X. Application of discrete event simulation in health care: a systematic review. BMC Health Serv Res. 2018;18(1):687.","journal-title":"BMC Health Serv Res"}],"container-title":["Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-50247-8_130-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T22:43:16Z","timestamp":1700952196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-50247-8_130-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783030502478","9783030502478"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-50247-8_130-1","relation":{},"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"28 May 2021, 00:00:00","order":1,"name":"received","label":"Received","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"13 April 2022, 00:00:00","order":2,"name":"accepted","label":"Accepted","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}